Trial Profile
A Phase 2, Multi-Center, Single-Blind, Placebo-Controlled Pharmacodynamic Evaluation of ICA-105665 in Epilepsy Patients With a Photo-Induced Paroxysmal Electroencephalographic (EEG) Response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2012
Price :
$35
*
At a glance
- Drugs ICA 105665 (Primary)
- Indications Reflex epilepsy
- Focus Therapeutic Use
- 19 Apr 2011 Clinical study results for ICA 105665 will be summarized at the Antiepileptic Drug Trials XI Conference in April 2011, according to a Icagen media release.
- 07 Mar 2011 Status changed from suspended to completed.
- 02 Feb 2011 The FDA's clinical hold on the IND for ICA 105665 has been removed, according to an Icagen media release.